HMGB1 and neoplasm: Although studies on HMGB1-mediated downstream signaling pathways have provided multiple potential strategies for OS treatment, such as inhibiting tumor progression by regulating pathways including p38 MAPK and miR-410-3p/HMGB1/NF-κB, the clinical application of these findings still faces significant obstacles.